2014 年至 2021 年美国中西部地区肺炎支原体的大环内酯类耐药性。
Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021.
机构信息
Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.
Department of Medicine, Division of Infectious Diseases, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.
出版信息
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0243221. doi: 10.1128/aac.02432-21. Epub 2022 Mar 21.
Abstract
The epidemiology of macrolide resistance in () in the United States is incompletely described. Using a PCR assay targeting common mutations associated with macrolide resistance in M. pneumoniae (23S rRNA gene, A2063G/A2064G), the frequency of macrolide resistance was estimated to be 10% based on analysis of 114 samples tested from January 2014 to September 2021 at Mayo Clinic Laboratories. Seasonality data showed the highest rates of M. pneumoniae infection in the fall/early winter.
摘要
在美国，（）中大环内酯类耐药的流行病学情况描述并不完整。本研究采用针对肺炎支原体中常见大环内酯类耐药相关突变（23S rRNA 基因，A2063G/A2064G）的 PCR 检测方法，对 2014 年 1 月至 2021 年 9 月在 Mayo 诊所实验室检测的 114 份样本进行分析，估计大环内酯类耐药的频率为 10%。季节性数据显示，肺炎支原体感染的高发期在秋季/初冬。
相似文献
1
Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021.2014 年至 2021 年美国中西部地区肺炎支原体的大环内酯类耐药性。
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0243221. doi: 10.1128/aac.02432-21. Epub 2022 Mar 21.
2
Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program.美国大环内酯类耐药肺炎支原体的国家监测结果
J Clin Microbiol. 2019 Oct 23;57(11). doi: 10.1128/JCM.00968-19. Print 2019 Nov.
3
Antibiotic sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant isolates from Beijing, China.中国北京 40 株肺炎支原体分离株的抗生素敏感性及大环内酯类耐药株的分子分析。
Antimicrob Agents Chemother. 2012 Feb;56(2):1108-9. doi: 10.1128/AAC.05627-11. Epub 2011 Nov 21.
4
Allele-specific real-time PCR testing for minor macrolide-resistant Mycoplasma Pneumoniae.针对小剂量大环内酯类耐药肺炎支原体的等位基因特异性实时 PCR 检测。
BMC Infect Dis. 2019 Jul 12;19(1):616. doi: 10.1186/s12879-019-4228-4.
5
Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis.通过实时聚合酶链反应和高分辨率熔解分析检测肺炎支原体中的大环内酯类耐药性。
Antimicrob Agents Chemother. 2008 Oct;52(10):3542-9. doi: 10.1128/AAC.00582-08. Epub 2008 Jul 21.
6
Evaluation of Lightmix Mycoplasma macrolide assay for detection of macrolide-resistant Mycoplasma pneumoniae in pneumonia patients.肺炎患者中检测大环内酯类耐药肺炎支原体的 Lightmix Mycoplasma macrolide 检测试剂盒评估。
Clin Microbiol Infect. 2019 Mar;25(3):383.e5-383.e7. doi: 10.1016/j.cmi.2018.10.006. Epub 2018 Oct 26.
7
Regional Differences in Prevalence of Macrolide Resistance among Pediatric Mycoplasma pneumoniae Infections in Hokkaido, Japan.日本北海道小儿肺炎支原体感染中大环内酯类耐药率的地区差异
Jpn J Infect Dis. 2016 May 20;69(3):186-90. doi: 10.7883/yoken.JJID.2015.054. Epub 2015 Jul 10.
8
[Survey of macrolide resistance in Mycoplasma pneumoniae in adult patients with community-acquired pneumonia in Beijing, China].[中国北京成年社区获得性肺炎患者肺炎支原体大环内酯类耐药性调查]
Zhonghua Jie He He Hu Xi Za Zhi. 2013 Dec;36(12):954-8.
9
Development of an endpoint genotyping assay to detect the Mycoplasma pneumoniae 23S rRNA gene and distinguish the existence of macrolide resistance-associated mutations at position 2063.开发一种终点基因分型检测方法，用于检测肺炎支原体23S rRNA基因，并区分2063位大环内酯耐药相关突变的存在情况。
J Microbiol Methods. 2016 Dec;131:130-134. doi: 10.1016/j.mimet.2016.10.017. Epub 2016 Oct 24.
10
gene of isolated from 2016 to 2019 and relationship between genotyping and macrolide resistance in Hokkaido, Japan.从 2016 年至 2019 年分离的基因与日本北海道地区基因型与大环内酯类耐药性的关系。
J Med Microbiol. 2021 Jun;70(6). doi: 10.1099/jmm.0.001365.
引用本文的文献
1
Efficacy and safety of doxycycline for severe Mycoplasma pneumoniae pneumonia in pediatric patients.多西环素治疗小儿重症肺炎支原体肺炎的疗效与安全性
Clin Exp Med. 2025 Jul 22;25(1):259. doi: 10.1007/s10238-025-01793-x.
2
Recent Macrolide Resistance Pattern of Mycoplasma Pneumonia in the World: A Systematic Review and Meta-Analysis.全球肺炎支原体近期的大环内酯类耐药模式：一项系统评价与Meta分析
Iran J Public Health. 2025 Mar;54(3):530-541. doi: 10.18502/ijph.v54i3.18246.
3
Macrolide resistance in in adult patients.成年患者中的大环内酯类耐药性。
Front Cell Infect Microbiol. 2025 Mar 4;15:1496521. doi: 10.3389/fcimb.2025.1496521. eCollection 2025.
4
Protective immunity induced by a novel P1 adhesin C-terminal anchored mRNA vaccine against infection in BALB/c mice.一种新型P1黏附素C末端锚定mRNA疫苗诱导的针对BALB/c小鼠感染的保护性免疫。
Microbiol Spectr. 2025 Mar 4;13(3):e0214024. doi: 10.1128/spectrum.02140-24. Epub 2025 Jan 20.
5
The epidemic characteristics of infection among children in Anhui, China, 2015-2023.中国安徽 2015-2023 年儿童感染的流行特征。
Microbiol Spectr. 2024 Oct 3;12(10):e0065124. doi: 10.1128/spectrum.00651-24. Epub 2024 Sep 3.
6
Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.儿童大环内酯类耐药肺炎支原体肺炎诊断与治疗专家共识。
World J Pediatr. 2024 Sep;20(9):901-914. doi: 10.1007/s12519-024-00831-0. Epub 2024 Aug 14.
7
miRNA, lncRNA and circRNA: targeted molecules with therapeutic promises in Mycoplasma pneumoniae infection.miRNA、lncRNA 和 circRNA：肺炎支原体感染中具有治疗前景的靶向分子。
Arch Microbiol. 2023 Jul 21;205(8):293. doi: 10.1007/s00203-023-03636-3.
8
Clinical Value of Metagenomics Next-Generation Sequencing in Antibiotic Resistance of a Patient with Severe Refractory Pneumonia: A Case Report.宏基因组学下一代测序在一名重症难治性肺炎患者抗生素耐药性检测中的临床价值：病例报告
Infect Drug Resist. 2023 Jul 13;16:4593-4597. doi: 10.2147/IDR.S419873. eCollection 2023.
9
Clinical characteristics of community-acquired pneumonia in children caused by mycoplasma pneumoniae with or without myocardial damage: A single-center retrospective study.肺炎支原体感染伴或不伴心肌损伤的儿童社区获得性肺炎的临床特征：一项单中心回顾性研究
World J Clin Pediatr. 2023 Jun 9;12(3):115-124. doi: 10.5409/wjcp.v12.i3.115.
10
Phenotypic and genotypic antimicrobial susceptibility patterns of the emerging human respiratory pathogen Mycoplasma amphoriforme isolated from the UK and Denmark.从英国和丹麦分离出的新兴人类呼吸道病原体弯曲菌属的表型和基因型抗菌药物敏感性模式。
J Antimicrob Chemother. 2022 Oct 28;77(11):3126-3129. doi: 10.1093/jac/dkac293.
本文引用的文献
1
Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA.美国俄亥俄州儿童的大环内酯类耐药肺炎支原体感染
Emerg Infect Dis. 2021 Jun;27(6):1588-1597. doi: 10.3201/eid2706.203206.
2
Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program.美国大环内酯类耐药肺炎支原体的国家监测结果
J Clin Microbiol. 2019 Oct 23;57(11). doi: 10.1128/JCM.00968-19. Print 2019 Nov.
3
Mycoplasma pneumoniae from the Respiratory Tract and Beyond.来自呼吸道及其他部位的肺炎支原体
Clin Microbiol Rev. 2017 Jul;30(3):747-809. doi: 10.1128/CMR.00114-16.
4
Mycoplasma pneumoniae: Current Knowledge on Nucleic Acid Amplification Techniques and Serological Diagnostics.肺炎支原体：关于核酸扩增技术和血清学诊断的当前知识
Front Microbiol. 2016 Mar 31;7:448. doi: 10.3389/fmicb.2016.00448. eCollection 2016.
5
The Evolution of Advanced Molecular Diagnostics for the Detection and Characterization of Mycoplasma pneumoniae.用于检测和鉴定肺炎支原体的先进分子诊断技术的发展
Front Microbiol. 2016 Mar 8;7:232. doi: 10.3389/fmicb.2016.00232. eCollection 2016.
6
New insights in the outbreak pattern of Mycoplasma pneumoniae.肺炎支原体爆发模式的新见解。
Int J Med Microbiol. 2015 Oct;305(7):705-8. doi: 10.1016/j.ijmm.2015.08.021. Epub 2015 Aug 22.
7
Real-time PCR detection of Mycoplasma pneumoniae in respiratory specimens.实时 PCR 检测呼吸道标本中的肺炎支原体。
Diagn Microbiol Infect Dis. 2013 Nov;77(3):202-5. doi: 10.1016/j.diagmicrobio.2013.07.016. Epub 2013 Sep 14.
8
Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis.通过实时聚合酶链反应和熔解曲线分析直接在临床标本中检测到法国肺炎支原体对大环内酯类药物的耐药性增加。
J Antimicrob Chemother. 2009 Jul;64(1):52-8. doi: 10.1093/jac/dkp160. Epub 2009 May 9.
9
Impact of weather factors on Mycoplasma pneumoniae pneumonia.天气因素对肺炎支原体肺炎的影响。
Thorax. 2009 Jun;64(6):507-11. doi: 10.1136/thx.2008.111237. Epub 2009 Mar 23.
Zotero 插件